Nebenwirkungen · Talmanco (previously Tadalafil Generics)
Talmanco 20 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-137559 · Präparat HOS-098059
In the pivotal placebo-controlled study of tadalafil for the treatment of PAH, a total of 323 patients were treated with tadalafil at doses ranging from 2.5 mg to 40 mg once daily and 82 patients were treated with placebo. The duration of treatment was 16 weeks. The overall frequency of discontinuation due to adverse events was low (tadalafil 11 %, placebo 16 %). Three hundred and fifty seven (357) patients who completed the pivotal study entered a long-term extension study. Doses studied were 20 mg and 40 mg once daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T02:00:00Z · SHA-256 9416206846678eeb980d8118e3703862499194c0ef267c815ee4a68563143115 · Passage 03c59b511d4cc4aa1e289f1284c32b95f46202f27ed0c619e60054f3872ea3f0 · Zeichen 397–923 im Abschnitt